DIPPER

 Prostate — Recruiting

DIPPER
While removal of the prostate is an effective treatment for many individuals with prostate cancer, around one third of people will experience return of their cancer (recurrence). Commonly, this is diagnosed when a blood test called prostate specific antigen, or PSA, becomes elevated. Provided there is no spread of cancer seen on scans, a ‘watch and wait’ surveillance approach, or radiotherapy are both reasonable treatment pathways in individuals deemed to be at low risk of further spread.

However, no-one knows yet what is the best treatment in this situation. While radiotherapy can be effective, it can result in side effects, and these can affect quality of life. It might be possible that personalised selection of individuals for surveillance using blood tests and newer imaging tests, such as PSMA PET scans, might identify a group of people who do not need additional radiation or other treatments and might be able to have similar outcomes for the cancers without the side effects. The DIPPER trial will compare cancer control and quality of life outcomes for individuals receiving either radiotherapy or surveillance following recurrence of their cancer after personalised patient selection, utilising the new imaging test and other clinical information.
If you think this trial might be right for you, please ask your doctor.
If you think this trial might be right for you, please ask your doctor.
Trial Title
A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance for biochemical recurrence after radical prostatectomy incorporating clinical and imaging-based risk stratification.
Cancer Type
Prostate
Trial Status
Recruiting
Protocol Number
ANZUP 2002
Study Chair
Matt Roberts and Louise Emmett
Patient Population
Men of low EAU risk (Gleason score 7 or less, PSA doubling time more than 12 months) with early biochemical recurrence (PSA < 0.5ng/mL) after radical prostatectomy and a negative PSMA PET/CT scan.
Recruitment Target
110
Acknowledgements
ANZUP Discretionary Funding; Below the Belt; Mundipharma
Participating Centres
NSW
St Vincent's Hospital - Sydney
Royal North Shore Hospital - Northern Sydney Local Health District

VIC
Peter MacCallum Cancer Centre

QLD
Royal Brisbane & Women's Hospital
Redcliffe Hospital